Your topics. New publications.

A compact browser notification when there’s something new. At most once a day — no account needed.

What interests you?

Optional and switchable off here at any time. We save your selected topics and device subscription; no email address is required. Privacy

Search the harborEN/DEAccount
Biological age & clocks
Research brief

Genetic epigenetic-clock scores and head and neck cancer risk in a case-control study

In 2189 head and neck squamous cell carcinoma cases and 2189 matched controls, higher polygenic scores for four epigenetic clocks were linked to higher cancer risk; Mendelian randomization suggested possible causal effects for HannumAge and GrimAge. [1]

Automatic summary · not editorially reviewed

The key findings

  1. The case-control study included 2189 HNSCC cases and 2189 age- and sex-matched controls. [1]

  2. Each standard deviation higher HannumAge polygenic score was associated with 25% higher HNSCC risk. [1]

  3. Mendelian randomization suggested potential causal effects of genetically predicted HannumAge and GrimAge on HNSCC risk. [1]

The source at a glance

Study type / format
Case-control study with two-sample Mendelian randomization (abstract).
Population / context
2189 head and neck squamous cell carcinoma cases and 2189 age- and sex-matched controls.
Summary based on
Study abstract
Original publication
July 2, 2026

Matched HNSCC case-control with clock polygenic scores

The study used a large case-control design with 2189 head and neck squamous cell carcinoma (HNSCC) cases and 2189 controls matched by age and sex. Genetic variants identified in genome-wide association studies for four epigenetic clocks (HannumAge, HorvathAge, GrimAge and PhenoAge) were combined into clock-specific polygenic scores. Logistic regression tested whether these scores were associated with HNSCC risk.

Supporting source [1]

Higher clock scores, higher HNSCC risk

Polygenic scores for all four clocks were higher in cases than controls. Each standard deviation higher HannumAge score was associated with 25% higher HNSCC risk (odds ratio 1.25, 95% confidence interval 1.10–1.41); the other three clocks showed weaker positive associations (odds ratios 1.06–1.10). People in the highest score quartile for all four clocks had 14%–25% higher risk than those in the lower three quartiles.

Supporting source [1]

Mendelian randomization hints at possible causal roles

Two-sample Mendelian randomization supported potential causal effects of genetically predicted HannumAge (odds ratio 1.24 per standard deviation, 95% confidence interval 1.09–1.42) and GrimAge (odds ratio 1.23, 95% confidence interval 0.98–1.56) on HNSCC risk, with consistent estimates in weighted median analyses. The GrimAge interval included 1.0. The authors describe biological aging as a potential etiologic mechanism and suggest clock-related genetic profiles might improve risk stratification.

Supporting source [1]

How to interpret this

Abstract only; the full text was not reviewed. The design is a case-control study plus two-sample Mendelian randomization, so associations are not proven causes. The GrimAge causal estimate had a confidence interval including 1.0, and the abstract reports no follow-up or replication details.

Based on the study abstract; the full paper, tables and supplementary data were not reviewed.

Source & supporting passages

[1]
Accelerated Biological Aging Increases the Risk of Head and Neck Cancer: Insights From Genetic Instruments of Epigenetic Clocks.

Wang J, Deng J, Xu Y, Tsai CW, Chang WS, Deng Y, Huang M, Bau DT, Li G, Gu J. · europepmc.org · July 2, 2026

Read the quoted passagesIn the language of the original source
  1. Finding 1 ↑

    2189 head and neck squamous cell carcinoma
  2. Finding 2 ↑

    each standard deviation increase in HannumAge PGS
  3. Finding 3 ↑

    MR analyses supported potential causal effects of

AI-assisted summary with linked source passages. No independent editorial or clinical review.

Our editorial method

Discussion

Community discussions

0 topics

Member contributions. Share sources, disclose commercial interests, and avoid personal medical or dosing advice.

Loading…